![](https://investorshub.advfn.com/uicon/48355.png?cb=1551739062)
Thursday, September 16, 2021 5:29:03 PM
"The expanded use authorization for bamlanivimab together with etesevimab provides a way to protect the significant number of people who, because of their situational exposure risk or medical condition, remain vulnerable to COVID-19," said Carl Hansen, Ph.D., CEO and President of AbCellera. "More than 535,000 patients have been treated with bamlanivimab alone or together with etesevimab, potentially keeping more than 25,000 patients out of the hospital and saving more than 10,000 lives. With this expanded authorization, these antibodies, which have been shown to be effective against the highly contagious Delta variant, can now be used to protect some of the most at-risk people exposed to the virus."
The expanded EUA is based on data from the Phase 3 BLAZE-2 trial that showed bamlanivimab prevented COVID-19 in nursing homes, reducing the risk of contracting the disease by up to 80 percent in nursing home residents and up to 57 percent among residents and staff of long-term care facilities. Eli Lilly and Company's (Lilly) study was conducted in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the COVID-19 Prevention Network (CoVPN).
Pseudovirus and authentic virus studies demonstrate that bamlanivimab and etesevimab together retain neutralization activity against the Alpha and Delta variants. On September 2nd, the Office of the Assistant Secretary for Preparedness and Response (ASPR), alongside the FDA, resumed the shipment and distribution of bamlanivimab and etesevimab administered together.
For information about the use of bamlanivimab and etesevimab together for the treatment and prevention of mild to moderate COVID-19 in high-risk patients under the FDA's emergency use authorization, please click here or contact Lilly's 24-hour support line at 1-855-LillyC19 (1-855-545-5921).
About AbCellera's Response to COVID-19
AbCellera initially mobilized its pandemic response platform against COVID-19 in March of 2020, resulting in the discovery of bamlanivimab, the first monoclonal antibody therapy for COVID-19 to reach human testing and to be authorized for emergency use by the FDA. Bamlanivimab alone and together with other antibodies has treated hundreds of thousands of patients, preventing COVID-19-related hospitalizations and death.
AbCellera's ongoing efforts to respond to the COVID-19 pandemic have identified thousands of unique anti-SARS-CoV-2 human antibodies. These include bamlanivimab, bebtelovimab, and other antibodies that are in various stages of testing by AbCellera and its partners.
AbCellera's pandemic response capabilities were developed over the past three years as part of the Defense Advanced Research Projects Agency (DARPA) Pandemic Prevention Platform (P3) program. The goal of the P3 program is to establish a robust technology platform for pandemic response capable of developing field-ready medical countermeasures within 60 days of isolation of an unknown viral pathogen.
New York Yankees and Duke Basketball
Recent ABCL News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 08:55:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:26:59 PM
- AbCellera Reports Q2 2024 Business Results • Business Wire • 08/06/2024 08:05:00 PM
- AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines • Business Wire • 07/31/2024 01:00:00 PM
- AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024 • Business Wire • 06/25/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 08:53:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 08:21:18 PM
- AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 • Business Wire • 05/28/2024 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 08:47:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:22:22 PM
- AbCellera Reports Q1 2024 Business Results • Business Wire • 05/07/2024 08:05:00 PM
- AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies • Business Wire • 05/01/2024 01:00:00 PM
- AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024 • Business Wire • 04/08/2024 04:05:00 PM
- AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024 • Business Wire • 04/03/2024 08:05:00 PM
- AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024 • Business Wire • 03/19/2024 08:05:00 PM
- AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions • Business Wire • 03/11/2024 01:00:00 PM
- AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024 • Business Wire • 03/05/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 07:12:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 09:49:40 PM
- AbCellera Announces Resignation of Board Member • Business Wire • 02/23/2024 09:30:00 PM
- AbCellera to Present at Upcoming Investor Conferences in March • Business Wire • 02/23/2024 01:15:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/20/2024 09:49:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 09:27:58 PM
- AbCellera Reports Full Year 2023 Business Results • Business Wire • 02/20/2024 09:05:00 PM
- AbCellera to Report Full Year 2023 Financial Results on February 20, 2024 • Business Wire • 01/23/2024 09:05:00 PM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM